Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 25, 2026, 9:17 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Orlando, Florida Clear all
Completed Not applicable Interventional

A Study of the TactiFlex SE Catheter and Volt PFA Generator in Subjects With PAF:

NCT06676072
View directory record Official record
Conditions
Atrial Fibrillation (AF), Atrial Arrhythmia, Paroxysmal AF, Drug Refractory Paroxysmal Atrial Fibrillation
Interventions
PFA Ablation catheter
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
29
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • Stanford, California + 24 more
Source: ClinicalTrials.gov public record
Updated May 31, 2026 · Synced Jul 25, 2026, 9:17 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Immunogenicity of High-dose Inactivated, Split-virion Influenza Vaccine Versus Standard Fluzone Vaccine in the Elderly

NCT00391053
View directory record Official record
Conditions
Orthomyxoviridae Infection, Influenza, Myxovirus Infection
Interventions
High-Dose Inactivated, Split-Virion Influenza Vaccine, Inactivated, Split-Virion Influenza Vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
65 Years and older
Enrollment
3,851 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
28
States / cities
Mesa, Arizona • Phoenix, Arizona • Tempe, Arizona + 25 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2016 · Synced Jul 25, 2026, 9:17 AM EDT
Completed Phase 3 Interventional Results available

Long-Term Safety and Efficacy Study of Fasinumab in Patients With Pain Due to Osteoarthritis (OA) of the Knee or Hip

NCT02683239
View directory record Official record
Conditions
Osteoarthritis of the Knee or Hip
Interventions
Fasinumab, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
5,331 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
50
States / cities
Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 44 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2023 · Synced Jul 25, 2026, 9:17 AM EDT
Completed Phase 2 Interventional

Efficacy and Safety of TAK-875 in Combination With Sitagliptin in Participants With Type 2 Diabetes Mellitus

NCT01414920
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Placebo, TAK-875, Sitagliptin, TAK-875 and Sitagliptin
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 80 Years
Enrollment
368 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
80
States / cities
Birmingham, Alabama • Brimingham, Alabama • Chandler, Arizona + 77 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2016 · Synced Jul 25, 2026, 9:17 AM EDT
Completed Phase 2 Interventional

Effects of LY3848575 Versus Placebo in Participants With Painful Distal Sensory Polyneuropathy

NCT06568042
View directory record Official record
Conditions
Neuropathic Pain, Distal Sensory Polyneuropathy
Interventions
LY3848575, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
558 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
24
States / cities
Chandler, Arizona • Phoenix, Arizona • Fresno, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Jul 25, 2026, 9:17 AM EDT
Completed Phase 3 Interventional Results available

A Study of Chemotherapy and Ramucirumab Versus Chemotherapy Alone in Second Line Non-Small Cell Lung Cancer (NSCLC) Participants Who Received Prior First Line Platinum-based Chemotherapy

NCT01168973
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Ramucirumab, Placebo (for Ramucirumab), Docetaxel
Biological · Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,253 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
97
States / cities
Phoenix, Arizona • Sedona, Arizona • Fayetteville, Arkansas + 93 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2019 · Synced Jul 25, 2026, 9:17 AM EDT
Completed No phase listed Observational

Examining Heart Attacks in Young Women

NCT00597922
View directory record Official record
Conditions
Acute Myocardial Infarction
Interventions
Not listed
Lead sponsor
Yale University
Other
Eligibility
18 Years to 55 Years
Enrollment
2,985 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
92
States / cities
Birmingham, Alabama • Mobile, Alabama • La Mesa, California + 76 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2020 · Synced Jul 25, 2026, 9:17 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and Recombinant Influenza Vaccine in Adult Participants 50 Years of Age and Older

NCT06695130
View directory record Official record
Conditions
COVID-19 Immunization, Influenza Immunization
Interventions
RIV (recombinant influenza vaccine), rC19 (dose 1), RIV + rC19 (dose 1), RIV + rC19 (dose 2), RIV + rC19 (dose 3), RIV + rC19 (dose 4), Placebo (0.9% NaCl)
Biological · Other
Lead sponsor
Sanofi
Industry
Eligibility
50 Years and older
Enrollment
980 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
12
States / cities
Phoenix, Arizona • Cerritos, California • Vista, California + 9 more
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Jul 25, 2026, 9:17 AM EDT
Completed Phase 2Phase 3 Interventional

A Paroxetine- and Placebo-Controlled Study of 50 mg/Day and 100 mg/Day of EB-1010 Among Outpatients With Major Depressive Disorder Who Have Responded Inadequately to Prior Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin Norepinephrine Reuptake Inhibitors (SNRIs)

NCT01318434
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
EB-1010 25mg BID, SSRI Active, EB-1010 50mg BID, Placebo
Drug
Lead sponsor
Euthymics BioScience, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
342 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
43
States / cities
Arcadia, California • Beverly Hills, California • National City, California + 39 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2015 · Synced Jul 25, 2026, 9:17 AM EDT
Not yet recruiting Phase 2 Interventional

DReAMzz- Dronabinol and Acetazolamide Medication for Sleep Apnea (ZZ). Dose Confirmation Crossover Study for IHL-42X in Subjects With Obstructive Sleep Apnea.

NCT07635563
View directory record Official record
Conditions
Obstructive Sleep Apnea (OSA)
Interventions
IHL-42X: 2.5 mg dronabinol + 125 mg acetazolamide, IHL-42X: 5 mg dronabinol + 125 mg acetazolamide, IHL-42X: 7.5 mg dronabinol + 125 mg acetazolamide, IHL-42X: 2.5 mg dronabinol + 250 mg acetazolamide, IHL-42X: 5 mg dronabinol + 250 mg acetazolamide, IHL-42X: 7.5 mg dronabinol + 250 mg acetazolamide, IHL-42X: 2.5 mg dronabinol + 375 mg acetazolamide, IHL-42X: 5 mg dronabinol + 375 mg acetazolamide, IHL-42X: 7.5 mg dronabinol + 375 mg acetazolamide, Placebo: Negative control
Drug
Lead sponsor
Incannex Healthcare Ltd
Industry
Eligibility
18 Years to 65 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
14
States / cities
Chula Vista, California • Brandon, Florida • Jacksonville, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Jul 25, 2026, 9:17 AM EDT
Recruiting Phase 2 Interventional

Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma

NCT05489887
View directory record Official record
Conditions
Neuroblastoma
Interventions
Naxitamab
Drug
Lead sponsor
Giselle Sholler
Other
Eligibility
12 Months to 21 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2036
U.S. locations
20
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Oakland, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Jul 25, 2026, 9:17 AM EDT
Terminated Phase 3 Interventional Results available

Extension to Study on Efficacy and Safety of Linzagolix for the Treatment of Endometriosis-associated Pain

NCT04372121
View directory record Official record
Conditions
Endometriosis
Interventions
75 mg linzagolix tablet, 200 mg linzagolix tablet, Add-back capsule (E2 1 mg / NETA 0.5 mg), Placebo tablet to match 75 mg linzagolix tablet, Placebo tablet to match 200 mg linzagolix tablet, Placebo capsule to match Add-back capsule
Drug
Lead sponsor
Kissei Pharmaceutical Co., Ltd.
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
23
States / cities
Little Rock, Arkansas • Norwalk, California • Greenwood Village, Colorado + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2025 · Synced Jul 25, 2026, 9:17 AM EDT
Terminated Phase 2 Interventional Results available

ARQ 197 for Participants With Relapsed or Refractory Germ Cell Tumors

NCT01055067
View directory record Official record
Conditions
Non-CNS Germ Cell Tumors (Seminomas and Nonseminomas)
Interventions
Tivantinib (ARQ 197)
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
16 Years and older · Male only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
6
States / cities
Los Angeles, California • Orlando, Florida • Indianapolis, Indiana + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2021 · Synced Jul 25, 2026, 9:17 AM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous Infusions of ABBV-951 in Subjects With Parkinson's Disease

NCT03033498
View directory record Official record
Conditions
Parkinson's Disease (PD)
Interventions
ABBV-951
Drug
Lead sponsor
AbbVie
Industry
Eligibility
45 Years to 85 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
7
States / cities
Glendale, California • Orlando, Florida • Grayslake, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 11, 2024 · Synced Jul 25, 2026, 9:17 AM EDT
Terminated Phase 3 Interventional Results available

Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy

NCT00858364
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Anemia, Cancer, Lung Cancer
Interventions
Darbepoetin alfa, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
2,549 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
277
States / cities
Anniston, Alabama • Birmingham, Alabama • Anchorage, Alaska + 243 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2022 · Synced Jul 25, 2026, 9:17 AM EDT
Completed Phase 1 Interventional

A Study on the Effect of Renal Function on the Pharmacakokinetics of RO5024048 (Parent of Prodrug RO5024048) Following Multiple Oral Dose Administration of RO5024048

NCT01099904
View directory record Official record
Conditions
Healthy Volunteer
Interventions
RO5024048
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
2
States / cities
Orlando, Florida • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Jul 25, 2026, 9:17 AM EDT
Terminated Phase 2 Interventional Results available

Study of Ravulizumab in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)

NCT04564339
View directory record Official record
Conditions
Lupus Nephritis, Immunoglobulin A Nephropathy
Interventions
Ravulizumab, Placebo, Background Therapy
Drug · Other
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
17
States / cities
San Dimas, California • Santa Monica, California • South Gate, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Jul 25, 2026, 9:17 AM EDT
Completed Phase 3 Interventional Results available

Long-Term Study Of CP-690,550 In Subjects With Ulcerative Colitis

NCT01470612
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
CP-690,550
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
944 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
75
States / cities
Mobile, Alabama • Tucson, Arizona • La Jolla, California + 42 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2021 · Synced Jul 25, 2026, 9:17 AM EDT
Active, not recruiting Phase 3 Interventional

A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )

NCT04849728
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
IVA337, Placebo
Drug
Lead sponsor
Inventiva Pharma
Industry
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
194
States / cities
Birmingham, Alabama • Dothan, Alabama • Madison, Alabama + 142 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Jul 25, 2026, 9:17 AM EDT
Completed Phase 1Phase 2 Interventional

Safety and Efficacy Trial of Imexon Plus DTIC in Advanced Malignant Melanoma

NCT00327600
View directory record Official record
Conditions
Malignant Melanoma
Interventions
imexon, DTIC
Drug
Lead sponsor
AmpliMed Corporation
Industry
Eligibility
Not listed
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
11
States / cities
Los Angeles, California • Santa Monica, California • Aurora, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2010 · Synced Jul 25, 2026, 9:17 AM EDT
Terminated Phase 3 Interventional

A Study of ASA404 or Placebo in Combination With Docetaxel in Second-line Treatment for (Stage IIIb/IV) Non-small Cell Lung Cancer

NCT00738387
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
ASA404, Placebo, docetaxel
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
88
States / cities
Huntsville, Alabama • Tucson, Arizona • Bentonville, Arkansas + 76 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2020 · Synced Jul 25, 2026, 9:17 AM EDT
Completed Phase 2 Interventional Results available

A Study of the Safety and Efficacy of GDC-0853 in Participants With Moderate to Severe Active Systemic Lupus Erythematosus

NCT02908100
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
GDC-0853, Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
19
States / cities
Birmingham, Alabama • Los Alamitos, California • Boca Raton, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated May 7, 2024 · Synced Jul 25, 2026, 9:17 AM EDT
Completed Phase 2 Interventional Results available

Phase 2 Study of TD-9855 to Treat Fibromyalgia

NCT01693692
View directory record Official record
Conditions
Fibromyalgia
Interventions
TD-9855 Group 1, TD-9855 Group 2, Placebo
Drug
Lead sponsor
Theravance Biopharma
Industry
Eligibility
18 Years to 65 Years
Enrollment
392 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
34
States / cities
Huntsville, Alabama • Goodyear, Arizona • El Cajon, California + 31 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2022 · Synced Jul 25, 2026, 9:17 AM EDT
Recruiting Phase 4 Interventional

Efficacy and Safety of Extended TARPEYO® Treatment Beyond 9 Months in Adult Patients With Primary IgA Nephropathy

NCT06712407
View directory record Official record
Conditions
IgA Nephropathy
Interventions
TARPEYO®
Drug
Lead sponsor
Calliditas Therapeutics AB
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
37
States / cities
Birmingham, Alabama • Glendale, Arizona • Fresno, California + 30 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Jul 25, 2026, 9:17 AM EDT